Phase 2 N=15 Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome
Epilepsy
Primary: Percent Change From Baseline in 28-Day Convulsive Seizure Frequency During Ataluren Treatment Period — 723.17 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants
Phase 2 N=52 Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
Severe Hypertriglyceridemia (sHTG)
Primary: Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants — 19.2; -37.2…
Phase 2 N=61 Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
Frown Lines
Primary: Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation — 85.7; 86.7; 93.8; 100 percentage of subjects
Phase 2 N=275 Reverse Genetic H9N2 Influenza Vaccine Study in Adults
Influenza
Primary: Number of Subjects With a Hemagglutination Inhibition (HI) Antibody Response to the Vaccine Strain (A/H9N2/Chicken/Hong Kong/G9/97) Associated With Seroconversion 21…
Phase 2 N=26 A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Prostate Cancer
Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants
Phase 2 N=217 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
Stage IV Pancreatic Cancer
Primary: Phase Ib: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=20 Denosumab for Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases. — 0 proportion of participants
Phase 2 N=368 University of Utah COVID-19 Hydrochloroquine Trial
Coronavirus Infection · Coronavirus · Infectious Disease
Primary: Duration of Viral Shedding — 9.532447; 10.39556 Days
Phase 2 N=78 A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline to Day 113 in DAS28-CRP — -1.06; -1.90; -1.87; -1.87 score on a scale — p=0.0296
Phase 2 N=12 Dual bNAb Treatment in Children
HIV Infection
Primary: Frequency of Treatment-associated Adverse Events (AEs) [Number of Participants With Treatment-associated Adverse Event(s) of Any Grade] — 4; 1; 19 Participants
Phase 2 N=50 A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.
Surgery
Primary: Opioid Consumption 12 Hours Post Operative — 19.4; 15.6 IV morphine mg equivalents
Phase 2 N=44 Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…
Phase 2 N=136 Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Atopic Dermatitis
Primary: Mean Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4 — -6.03; -6.44; -4.84 score on a scale — p=0.356
Phase 2 N=58 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants